摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-cyclopropyl-1-[5-[4-[1-(4-fluorophenyl)sulfonylcyclopropyl]-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyrimidin-2-yl]urea | 1101803-96-6

中文名称
——
中文别名
——
英文名称
3-cyclopropyl-1-[5-[4-[1-(4-fluorophenyl)sulfonylcyclopropyl]-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyrimidin-2-yl]urea
英文别名
1-cyclopropyl-3-[5-[4-[1-(4-fluorophenyl)sulfonylcyclopropyl]-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyrimidin-2-yl]urea
3-cyclopropyl-1-[5-[4-[1-(4-fluorophenyl)sulfonylcyclopropyl]-6-[(3S)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyrimidin-2-yl]urea化学式
CAS
1101803-96-6
化学式
C26H28FN7O4S
mdl
——
分子量
553.617
InChiKey
FESGCEFVKPLEKI-INIZCTEOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    39
  • 可旋转键数:
    7
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    148
  • 氢给体数:
    2
  • 氢受体数:
    10

文献信息

  • Compounds - 945
    申请人:PIKE Kurt Gordon
    公开号:US20090018134A1
    公开(公告)日:2009-01-15
    A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.
    公式(I)的化合物或其药用盐,其制备方法,含有它们的药物组合物以及它们在治疗中的用途,例如在治疗增殖性疾病如癌症,特别是由mTOR激酶和/或一个或多个PI3K酶介导的疾病。
  • TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
    申请人:AstraZeneca AB
    公开号:EP2074118A2
    公开(公告)日:2009-07-01
  • [EN] COMPOUNDS 945<br/>[FR] COMPOSÉS 945
    申请人:ASTRAZENECA AB
    公开号:WO2009007748A2
    公开(公告)日:2009-01-15
    A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.
查看更多